GLAXOSMITHKLINE has confirmed it is experiencing a "supply constraint" of its Twinrix Junior combined hepatitis A and hepatitis B vaccine, due to a current high demand for hepatitis-B containing vaccines in Australia.
The company expects Twinrix Junior to be back in stock by the end of Nov 2017, while Twinrix Adult is now back in stock following a recent supply issue.
There's also an ongoing constraint on Engerix-B adult doses after recent shortages, with production now back to normal levels but some time taken to rebuild capacity.
There is an intermittent constraint of Engerix-B paediatric doses for the private market, with this issue expected to be resolved by the end of 2017, the company said.
GSK said supply of its vaccines containing hepatitis B to government programs is not impacted by the shortages.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Oct 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Oct 17